ArticleDiscover oncology2025
Identification of NOTCH2 as a prognostic marker for cholangiocarcinoma.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundCholangiocarcinoma (CCA) is a rare malignancy originating from the hepatobiliary epithelium, accounting for 3–5% of all gastrointestinal cancers worldwide. CCA is notoriously difficult to diagnose and is associated with a high mortality rate. While most cases lack identifiable predisposing factors, emerging evidence suggests that molecular therapies targeting fibroblast growth factor receptor and isocitrate dehydrogenase show promise for specific CCA patients.
methodsThis study employed a series of comprehensive bioinformatics analyses, survival analyses, immunohistochemistry, and drug sensitivity screening.
resultsWe decoded the dynamic changes in cell populations between cholangiocarcinoma and paired healthy tissues, revealing that JAG1-NOTCH signaling significantly contributes to CCA pathogenesis. Higher NOTCH2 expression was correlated with poor prognosis and validated as a proliferative promoter in cell lines. Additionally, we identified four potential drugs targeting NOTCH2.
conclusionsThese findings provide new insights into the molecular basis of NOTCH2-mediated promotion of tumor activity and suggest NOTCH2 as a potential therapeutic target for CCA treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.